Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

Core Viewpoint - Kamada Ltd. is set to release its financial results for Q4 and the fiscal year ending December 31, 2025, on March 11, 2026, before U.S. market opening [1] Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in products for rare and serious conditions, particularly in the specialty plasma-derived therapies field [3] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of its outstanding shares [3] Growth Strategy - Kamada's growth strategy focuses on four primary pillars: 1. Organic growth of its specialty plasma therapies portfolio, including six FDA-approved products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF®, and HEPAGAM B®, along with KAMRAB® and equine-based anti-snake venom products [3] 2. Distribution of third-party pharmaceutical products in Israel and MENA through in-licensing partnerships, including the launch of several biosimilar products [3] 3. Expansion of plasma collection operations to support revenue growth from the sale of normal source plasma and meet the demand for hyper-immune plasma, with three operating centers in Texas [3] 4. Pursuit of mergers, acquisitions, and collaborations to enhance its product portfolio and leverage financial strength for long-term growth [3]